342 related articles for article (PubMed ID: 21278796)
21. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype.
Xie Y; Skytting B; Nilsson G; Brodin B; Larsson O
Cancer Res; 1999 Aug; 59(15):3588-91. PubMed ID: 10446966
[TBL] [Abstract][Full Text] [Related]
22. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.
Garofalo C; Mancarella C; Grilli A; Manara MC; Astolfi A; Marino MT; Conte A; Sigismund S; Carè A; Belfiore A; Picci P; Scotlandi K
Mol Endocrinol; 2012 Sep; 26(9):1603-16. PubMed ID: 22798295
[TBL] [Abstract][Full Text] [Related]
23. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside.
Olmos D; Tan DS; Jones RL; Judson IR
Cancer J; 2010; 16(3):183-94. PubMed ID: 20526094
[TBL] [Abstract][Full Text] [Related]
24. Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor.
Wood ER; Shewchuk L; Hassel A; Nichols J; Truesdale AT; Smith D; Carter HL; Weaver K; Barrett G; Leesnitzer T; Alvarez E; Bardera AI; Alamillo A; Cantizani J; Martin J; Smith GK; Jensen DE; Xie H; Mook R; Kumar R; Kuntz K
Biochem Pharmacol; 2009 Dec; 78(12):1438-47. PubMed ID: 19665448
[TBL] [Abstract][Full Text] [Related]
25. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
Adachi Y; Lee CT; Carbone DP
Novartis Found Symp; 2004; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
[TBL] [Abstract][Full Text] [Related]
26. Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats.
Wang Y; Malkowski M; Hailey J; Turek-Etienne T; Tripodi T; Pachter JA
J Exp Ther Oncol; 2004 Jul; 4(2):111-9. PubMed ID: 15500006
[TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling.
Shen MR; Hsu YM; Hsu KF; Chen YF; Tang MJ; Chou CY
Carcinogenesis; 2006 May; 27(5):962-71. PubMed ID: 16400188
[TBL] [Abstract][Full Text] [Related]
28. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
Scotlandi K; Benini S; Sarti M; Serra M; Lollini PL; Maurici D; Picci P; Manara MC; Baldini N
Cancer Res; 1996 Oct; 56(20):4570-4. PubMed ID: 8840962
[TBL] [Abstract][Full Text] [Related]
30. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
32. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.
Ulanet DB; Ludwig DL; Kahn CR; Hanahan D
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10791-8. PubMed ID: 20457905
[TBL] [Abstract][Full Text] [Related]
33. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
[TBL] [Abstract][Full Text] [Related]
34. The monoclonal HBA-71 antibody modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor I.
Hamilton G; Mallinger R; Hofbauer S; Havel M
Thymus; 1991 Aug; 18(1):33-41. PubMed ID: 1656551
[TBL] [Abstract][Full Text] [Related]
35. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
36. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
Bauer TW; Fan F; Liu W; Camp ER; Yang A; Somcio RJ; Bucana CD; Singh R; Ellis LM
Ann Surg Oncol; 2007 Oct; 14(10):2838-46. PubMed ID: 17653802
[TBL] [Abstract][Full Text] [Related]
37. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
[TBL] [Abstract][Full Text] [Related]
38. β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.
Zheng H; Shen H; Oprea I; Worrall C; Stefanescu R; Girnita A; Girnita L
Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20620-5. PubMed ID: 23188799
[TBL] [Abstract][Full Text] [Related]
39. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
[TBL] [Abstract][Full Text] [Related]
40. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
Jin M; Wang J; Buck E; Mulvihill MJ
Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
